Arantxa Eraso

Prof. Dr. Arantxa Eraso

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in JMIR Research Protocols
Verified
Journal Article
Open access
VWValentin Walker
Valentin Walker
ACAnne Crijns
Anne Crijns
HLHans Langendijk
Hans Langendijk
DSDaan Spoor
Daan Spoor
RVRozemarijn Vliegenthart
Rozemarijn Vliegenthart
Sophie JacobSophie Jacob
Sophie Jacob
Breast cancer is the most common cancer among women, and radiotherapy plays a major role in its treatment. However, breast cancer radiotherapy can lead to incidental irradiation of the heart, resulting in an increased risk for a variety of heart diseases arising many years after radiotherapy. Therefore, identifying breast cancer patients at the highest risk for radiation-induced cardiac complications is crucial for developing strategies for primary and secondary prevention, which may contribute to healthy aging. There is still a need for precise knowledge on the relationship between radiation dose to specific cardiac structures and early subclinical cardiac changes and their occurrence over time that could finally lead to cardiac complications. The MEDIRAD EARLY HEART study aims to identify and validate new cardiac imaging and circulating biomarkers of radiation-induced cardiovascular changes arising within first 2 years of breast cancer radiotherapy and to develop risk models integrating these biomarkers combined with precise dose metrics of cardiac structures based on three-dimensional dosimetry. The EARLY HEART study is a multicenter, prospective cohort study in which 250 women treated for breast cancer and followed for 2 years after radiotherapy will be included. Women treated with radiotherapy without chemotherapy for a unilateral breast cancer and aged 40-75 years meet the inclusion criteria. Baseline and follow-up data include cardiac measurements based on two-dimensional speckle-tracking echocardiography, computed tomography coronary angiography, cardiac magnetic resonance imaging, and a wide panel of circulating biomarkers of cardiac injury. The absorbed dose will be evaluated globally for the heart and different substructures. Furthermore, the dose-response relationship will allow modeling the radiation-induced occurrence and evolution of subclinical cardiac lesions and biomarkers to develop prediction models. This study details the protocol of the MEDIRAD EARLY HEART study and presents the main limits and advantages of this international project. The inclusion of patients began in 2017. Preliminary results are expected to be published in 2019, and complete analysis should be published in 2021. The MEDIRAD EARLY HEART study will allow identifying the main cardiac imaging and blood-based determinants of radiation-induced cardiac injuries to better propose primary and secondary preventive measures in order to contribute to enhanced patient care and quality of life. ClinicalTrials.gov NCT03297346; https://clinicaltrials.gov/ct2/show/NCT03297346 (Archived by WebCite at http://www.webcitation.org/72KS7MIUU). RR1-10.2196/9906.

8 August 2023 in Cancers
Verified
Journal Article
Open access
PDF file
XSXavier Sanz
Xavier Sanz
AEArantxa Eraso
Arantxa Eraso
RIReyes Ibáñez
Reyes Ibáñez
Rachel Aurora WilliamsRachel Aurora Williams
Rachel Aurora Williams
MAManuel Algara
Manuel Algara
Conservative surgery is the preferred treatment in the management of breast cancer followed by adjuvant whole-breast irradiation. Since the tumor bed is the main site of relapse, boost doses are conveniently administered according to risk factors for local relapse to increase the efficacy of the treatment. The benefit of a radiation boost is well established and it can be performed by several techniques like brachytherapy, external radiation or intraoperative radiotherapy. Greater precision in localizing the tumor cavity, immediacy and increased biological response are the main advantages of intraoperative boost irradiation. This modality of treatment can be performed by means of mobile electron accelerators or low-photon X-ray devices. There is a lot of research and some published series analyzing the results of the use of an intraoperative boost as an adjuvant treatment, after neoadjuvant systemic therapy and in combination with some reconstructive surgeries. This review discusses advantages of intraoperative radiotherapy and presents the main results of a boost in terms of local control, survival, tolerance and cosmesis.

27 August 2020 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
MFMagdalena Fundowicz
Magdalena Fundowicz
AAArtur Aguiar
Artur Aguiar
CCCarla Lopes de Castro
Carla Lopes de Castro
MTMaria Glòria Torras
Maria Glòria Torras
LDLetizia Deantonio
Letizia Deantonio
FGFerran Guedea
Ferran Guedea
Purpose: To perform a clinical audit to assess adherence to standard clinical practice for the diagnosis, treatment, and follow-up of patients undergoing radiotherapy for rectal cancer treatment in four European countries. Materials and methods: Multi-institutional, retrospective cohort study of 221 patients treated for rectal cancer in 2015 at six European cancer centres. Clinical indicators applicable to general radiotherapy processes were evaluated. All data were obtained from electronic medical records. Results: The audits were performed in the year 2017. We found substantial inter-centre variability in adherence to standard clinical practices: 1) presentation of cases at departmental clinical sessions (range, 0–100%) or multidisciplinary tumour board (50–95%); 2) pretreatment MRI (61.5–100%) and thoracoabdominal CT (15.0–100%). Large inter-centre differences were observed in the mean interval between biopsy and first visit to the radiotherapy department (range, 21.6–58.6 days) and between the first visit and start of treatment (15.1–38.8 days). Treatment interruptions ≥ 1 day occurred in 43.9% (2.5–90%) of cases overall. Treatment compensation was performed in 2.1% of cases. Treatment was completed in the prescribed time in 55.7% of cases. Conclusions: This multi-institutional clinical audit revealed that most centres adhered to standard clinical practices for most of the radiotherapy processes-related variables assessed. However, the audit revealed marked inter-centre variability for certain quality indicators, particularly inconsistent record keeping. Multiple targets for improvement and/or harmonisation were identified, confirming the value of routine clinical audits to detect potential deviations from standard clinical practice.

1 April 2025 in Radiology: Cardiothoracic Imaging
Verified
Journal Article
Closed access
JLJérôme Lamy
Jérôme Lamy
DSDaan S. Spoor
Daan S. Spoor
JLJohannes A. Langendijk
Johannes A. Langendijk
RVRozemarijn Vliegenthart
Rozemarijn Vliegenthart
AEArantxa Eraso
Arantxa Eraso
KBKai Borm
Kai Borm
Higher cardiac radiation doses in participants with breast cancer treated with radiation therapy after lumpectomy were associated with increased risk of reduced left ventricular global longitudinal strain at 2-year follow-up cardiac MRI.

1 June 2026 in Radiology: Cardiothoracic Imaging
Verified
Journal Article
Closed access
EMElie Mousseaux
Elie Mousseaux
DCDamian Craiem
Damian Craiem
RVRozemarijn Vliegenthart
Rozemarijn Vliegenthart
Sophie JacobSophie Jacob
Sophie Jacob
AEArantxa Eraso
Arantxa Eraso
SCSusana Constantino
Susana Constantino
Two years after breast cancer radiotherapy, cardiac CT demonstrated dose-associated progression of coronary artery calcification, particularly in the presence of preexisting calcification, while coronary stenosis progression was unrelated to radiation dose.

1 August 2015 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
FGFerran Guedea
Ferran Guedea
AEArantxa Eraso
Arantxa Eraso
DADavid Azria
David Azria
PLPedro Lara
Pedro Lara
FIFrançoise Izar
Françoise Izar